Develops sustained-delivery drug treatments for patients with serious retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
10-K for FY2025, filed Mar 5, 2026EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative…View ↗
DURAVYU is currently in Phase 3 clinical trials for the potential treatment of wet AMD and DME, the two largest retinal disease markets.…View ↗
The proven Durasert® drug delivery technology (Durasert®) has been safely administered to thousands of patient eyes across four products…View ↗
Pharmaceutical partners pay upfront license fees and milestone payments when specified goals are met; EyePoint also receives royalties when partners sell licensed products. It earns product revenue through commercial supply agreements.
10-K for FY2025, filed Mar 5, 2026License and collaboration agreement revenue — The Company analyzes each element of its license and collaboration arrangements to determine…View ↗
The Company recognizes sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the…View ↗
Royalties — The Company recognizes revenue from license arrangements with its commercial partners’ net sales of products. Such revenues are…View ↗
For the years ended December 31, 2025 and 2024, the Company’s product revenues were primarily from the Company’s existing supply agreements…View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$31.4M
10-K for FY2025, filed Mar 5, 2026
$31.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
|
5.1%
FY2022: 96%
|
Product sales, net, FY2025
$1.6M Sources
|
|
|
License and Collaboration Agreement
Licensed
10-K for FY2025, filed Mar 5, 2026 |
53%
FY2022: 0.9%
|
License and Collaboration Agreement, FY2025
$16.7M Sources
|
Licensed |
|
Royalty Income
Licensed
10-K for FY2025, filed Mar 5, 2026 |
42%
FY2022: 2.8%
|
Royalty Income, FY2025
$13M Sources
|
Licensed |
Pharmaceutical partners license rights to develop and commercialize products; EyePoint also supplies products to partners under commercial supply agreements, including ANI for U.S. sales.
10-K for FY2025, filed Mar 5, 2026On May 17, 2023, the Company entered into a PRA with ANI. Under the PRA, the Company granted to ANI an exclusive and sublicensable right…View ↗
The Company and ANI also entered into a commercial supply agreement (CSA), pursuant to which, during the term of the PRA, the Company…View ↗
The Company entered into an Exclusive License Agreement on November 2, 2018, as amended by a Memorandum of Understanding dated March 1…View ↗
No. It lost $232M in FY2025.
8-K, filed Nov 12, 2026
On August 17, 2026, we announced the Phase 3 LUGANO trial did not achieve the primary endpoint of statistical non-inferiority in mean…View ↗
8-K, filed Oct 19, 2026
On October 17, 2026, following review of topline results from LUCIA, the second pivotal Phase 3 clinical trial evaluating DURAVYU™ for the…View ↗
Shrinking. Revenue fell 15% in 4 years, from $36.9M in FY2021 to $31.4M in FY2025, about 4% a year.
Partner-led product commercialization
The older report described YUTIQ as a product EyePoint marketed; the latest report describes a license to ANI for development and commercialization, with EyePoint earning license revenue.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 5, 2026Our commercial product, YUTIQ®, is a once every three-year treatment for chronic non-infectious uveitis affecting the posterior segment of…View ↗
Lead candidate advances
The lead candidate moved from earlier studies for wet AMD and non-proliferative diabetic retinopathy, with DME development planned, to pivotal trials for wet AMD and diabetic macular edema.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 5, 2026EYP-1901 is an investigational product deploying a bioerodible Durasert insert of vorolanib, a selective and patent protected TKI, that…View ↗
Competes with REGENXBIO, Adverum Biotechnologies, 4D Molecular Therapeutics, Merck, Ollin Biosciences, Ocular Therapeutix, Kodiak Sciences, and Oculis Holding
10-K for FY2025, filed Mar 5, 2026REGENXBIO Inc., Adverum Biotechnologies, Inc., 4D Molecular Therapeutics (4DMT), Merck (EyeBio), Ollin Biosciences, Inc., as well as…View ↗
Loading...